Suanfarma Suanfarma

X
[{"orgOrder":0,"company":"Sandoz B2B","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals for Oxiconazole Nitrate

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            ANI Pharmaceuticals has acquired new drug applications for OXISTAT Lotion, VEREGEN Ointment, and Pandel Cream and the abbreviated new drug application for ApexiCon E Cream from Sandoz Inc. Pandel Cream will be transitioned later upon receiving the requisite approvals.

            Lead Product(s): Oxiconazole Nitrate

            Therapeutic Area: Infections and Infectious Diseases Product Name: Oxistat

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: ANI Pharmaceuticals Inc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition April 06, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY